| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11844784 | SLAYBACK PHARMA LLC | Stable pharmaceutical compositions of bendamustine |
Jul, 2042
(18 years from now) | |
Vivimusta is owned by Slayback Pharma Llc.
Vivimusta contains Bendamustine Hydrochloride.
Vivimusta has a total of 1 drug patent out of which 0 drug patents have expired.
Vivimusta was authorised for market use on 07 December, 2022.
Vivimusta is available in solution;intravenous dosage forms.
The generics of Vivimusta are possible to be released after 29 July, 2042.
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 December, 2022
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
VIVIMUSTA family patents
